Montanova Capital, LLC 13F holdings, Q2 2022
Montanova Capital, LLC disclosed 89 US equity positions worth $2.6bn in its Q2 2022 13F filing. Its largest position is RPRX at 4.9% of the reported book, followed by UNH and UNP. Versus Q1 2022 it opened 23 new positions, added to 22, reduced 18 and exited 21.
- $2.6bn
- Reported equity book Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
- 89
- Positions Distinct securities in the equity book with a reported value above zero. Options are excluded.
- 4.9%
- Largest position The largest single position as a share of the reported equity book.
- 36.4%
- Top 10 weight The ten largest positions together, as a share of the reported equity book.
- 42
- Effective positions 1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
- 51
- Quarters on file since Q4 2013 Quarters for which this manager's 13F holdings are on record.
Holdings
Against Q1 2022: 23 new, 22 added, 18 reduced, 21 exited
| RPRX ROYALTY PHARMA PLC | 4.9% | +52% | added |
| UNH UNITEDHEALTH GROUP INC | 4.7% | 0.0% | held |
| UNP UNION PACIFIC CORP | 4.3% | −13% | reduced |
| LVS LAS VEGAS SANDS CORP | 3.7% | +28% | added |
| HUM HUMANA INC | 3.5% | +4.6% | added |
| OTIS OTIS WORLDWIDE CORP | 3.5% | 0.0% | held |
| IQV IQVIA HLDGS INC | 3.2% | +1.4% | added |
| ITCIEUR INTRA-CELLULAR THERAPIES INC | 2.9% | −13% | reduced |
| EL LAUDER ESTEE COS INC | 2.8% | −21% | reduced |
| KURA KURA ONCOLOGY INC | 2.8% | +3.2% | added |
| TPR TAPESTRY INC | 2.6% | −3.1% | reduced |
| CNC CENTENE CORP DEL | 2.6% | −33% | reduced |
| MA MASTERCARD INC | 2.5% | +9.5% | added |
| TMO THERMO FISHER SCIENTIFIC INC | 2.5% | +5.5% | added |
| MSFT MICROSOFT CORP | 2.4% | −58% | reduced |
| V VISA INC | 2.4% | −26% | reduced |
| MRTXEUR MIRATI THERAPEUTICS INC | 2.4% | +87% | added |
| DHR DANAHER CORP DEL | 2.1% | −6.2% | reduced |
| AGIO AGIOS PHARMACEUTICALS INC | 2.0% | +97% | added |
| ACLXGBX ARCELLX INC | 1.7% | +61% | added |
| COR CENCORA INC | 1.7% | −18% | reduced |
| CANADIAN PAC RY LTD no ticker | 1.7% | – | new |
| XYZ BLOCK INC | 1.6% | – | new |
| INSM INSMED INC | 1.6% | +58% | added |
| VTRS VIATRIS INC | 1.5% | – | new |
| FIS FIDELITY NATL INFORMATION SV | 1.5% | – | new |
| HLT HILTON WORLDWIDE HLDGS INC | 1.5% | −0.6% | reduced |
| MAR MARRIOTT INTL INC NEW | 1.5% | −5.4% | reduced |
| HORIZON THERAPEUTICS PUB L no ticker | 1.5% | – | new |
| KEZAR LIFE SCIENCES INC no ticker | 1.4% | +213% | added |
| MCK MCKESSON CORP | 1.3% | +7.0% | added |
| DIS DISNEY WALT CO | 1.3% | – | new |
| GPN GLOBAL PMTS INC | 1.2% | – | new |
| 290A CHINOOK THERAPEUTICS INC | 1.2% | +24% | added |
| RH RH | 1.1% | −27% | reduced |
| MQ MARQETA INC | 1.1% | −14% | reduced |
| EXMOC EXXON MOBIL CORP | 0.9% | – | new |
| STRO SUTRO BIOPHARMA INC | 0.9% | +24% | added |
| EYPT EYEPOINT INC | 0.9% | +2.0% | added |
| GFL GFL ENVIRONMENTAL INC | 0.9% | −60% | reduced |
| MNST MONSTER BEVERAGE CORP NEW | 0.9% | – | new |
| CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.8% | – | new |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 0.8% | −34% | reduced |
| POINT BIOPHARMA GLOBAL INC no ticker | 0.8% | 0.0% | held |
| MTCH MATCH GROUP INC NEW | 0.8% | – | new |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 0.7% | +10% | added |
| PHVS PHARVARIS N V | 0.7% | 0.0% | held |
| MRNS* MARINUS PHARMACEUTICALS INC | 0.6% | +27% | added |
| FULC FULCRUM THERAPEUTICS INC | 0.6% | +28% | added |
| NOW SERVICENOW INC | 0.5% | – | new |
Exited since Q1 2022
| AMZN AMAZON COM INC | 4.5% | $147m |
| SPGI S&P GLOBAL INC | 2.6% | $84.8m |
| SCHW SCHWAB CHARLES CORP | 2.5% | $82.9m |
| JNJ JOHNSON & JOHNSON | 2.2% | $73.6m |
| XLE SELECT SECTOR SPDR TR | 1.6% | $53.0m |
| BBWI BATH & BODY WORKS INC | 1.5% | $49.6m |
| DECK DECKERS OUTDOOR CORP | 1.2% | $39.0m |
| WYNN WYNN RESORTS LTD | 0.9% | $29.2m |
| NTRA NATERA INC | 0.7% | $23.8m |
| CANO HEALTH INC no ticker | 0.7% | $23.3m |
| XOP SPDR SERIES TRUST | 0.7% | $22.2m |
| XENE XENON PHARMACEUTICALS INC | 0.6% | $21.2m |
| IOVA IOVANCE BIOTHERAPEUTICS INC | 0.2% | $6.8m |
| AUPH AURINIA PHARMACEUTICALS INC | 0.1% | $4.3m |
| INOZYME PHARMA INC no ticker | 0.1% | $4.1m |
| OPY ACQUISITION CORP I no ticker | 0.06% | $2.0m |
| DECIBEL THERAPEUTICS INC no ticker | 0.02% | $801k |
| MGTX MEIRAGTX HLDGS PLC | 0.01% | $479k |
| EUROPEAN BIOTECH ACQUTN CORP no ticker | 0.0% | $20.0k |
| FRAZIER LIFESCIENCES ACQU CO no ticker | 0.0% | $7.0k |
| EUCRATES BIOMEDICAL ACQU COR no ticker | 0.0% | $6.0k |
Sector mix
Book over time
Every quarter on file (51)
| Quarter | Positions | Equity book |
|---|---|---|
| Q2 2026 | 95 | $4.8bn |
| Q1 2026 | 88 | $3.7bn |
| Q4 2025 | 90 | $4.0bn |
| Q3 2025 | 90 | $3.3bn |
| Q2 2025 | 95 | $2.7bn |
| Q1 2025 | 99 | $2.5bn |
| Q4 2024 | 94 | $2.7bn |
| Q3 2024 | 96 | $2.8bn |
| Q2 2024 | 97 | $2.5bn |
| Q1 2024 | 99 | $2.4bn |
| Q4 2023 | 87 | $2.2bn |
| Q3 2023 | 87 | $1.9bn |
| Q2 2023 | 100 | $1.9bn |
| Q1 2023 | 92 | $2.1bn |
| Q4 2022 | 89 | $2.4bn |
| Q3 2022 | 72 | $2.4bn |
| Q2 2022 | 89 | $2.6bn |
| Q1 2022 | 87 | $3.3bn |
| Q4 2021 | 94 | $5.2bn |
| Q3 2021 | 105 | $5.9bn |
| Q2 2021 | 121 | $6.7bn |
| Q1 2021 | 105 | $6.7bn |
| Q4 2020 | 106 | $7.0bn |
| Q3 2020 | 92 | $5.5bn |
| Q2 2020 | 79 | $4.7bn |
| Q1 2020 | 64 | $3.7bn |
| Q4 2019 | 37 | $4.3bn |
| Q3 2019 | 38 | $3.7bn |
| Q2 2019 | 39 | $4.0bn |
| Q1 2019 | 34 | $2.8bn |
| Q4 2018 | 19 | $1.3bn |
| Q3 2018 | 21 | $4.3bn |
| Q2 2018 | 19 | $3.7bn |
| Q1 2018 | 18 | $3.9bn |
| Q4 2017 | 28 | $4.2bn |
| Q3 2017 | 16 | $3.4bn |
| Q2 2017 | 19 | $3.2bn |
| Q1 2017 | 36 | $3.1bn |
| Q4 2016 | 39 | $2.9bn |
| Q3 2016 | 26 | $2.6bn |
| Q2 2016 | 22 | $2.2bn |
| Q1 2016 | 20 | $2.5bn |
| Q4 2015 | 22 | $1.9bn |
| Q3 2015 | 15 | $831m |
| Q2 2015 | 31 | $2.1bn |
| Q1 2015 | 27 | $1.6bn |
| Q4 2014 | 26 | $1.4bn |
| Q3 2014 | 28 | $1.1bn |
| Q2 2014 | 32 | $1.1bn |
| Q1 2014 | 29 | $831m |
| Q4 2013 | 34 | $746m |
Where Montanova Capital, LLC was early
| APD AIR PRODS & CHEMS INC | Q1 2014 | 9 of 169 | 4.8% | Exited by Q1 2021 | +148% |
| NEE NEXTERA ENERGY INC | Q2 2014 | 5 of 182 | 4.9% | Exited by Q3 2015 | −4.3% |
| ASH ASHLAND INC NEW | Q2 2014 | 12 of 129 | 1.3% | Exited by Q4 2014 | −4.3% |
| PEP PEPSICO INC | Q2 2014 | 14 of 139 | 2.6% | Exited by Q4 2014 | +4.2% |
| PPG PPG INDS INC | Q3 2014 | 2 of 138 | 1.9% | Exited by Q1 2017 | −3.7% |
| MDT MEDTRONIC PLC | Q3 2014 | 10 of 173 | 3.1% | Exited by Q2 2026 | +40% |
| CDK CDK GLOBAL INC | Q4 2014 | 5 of 139 | 3.7% | Exited by Q2 2015 | +15% |
| MSTR MICROSTRATEGY INC | Q4 2014 | 5 of 143 | 1.3% | Exited by Q3 2015 | +4.7% |
| FIVE FIVE BELOW INC | Q1 2015 | 3 of 174 | 1.1% | Exited by Q3 2024 | +206% |
| ARMK ARAMARK | Q1 2015 | 6 of 177 | 6.2% | Exited by Q4 2019 | +38% |
| NXPI NXP SEMICONDUCTORS N V | Q1 2015 | 16 of 228 | 3.8% | Exited by Q4 2021 | +95% |
| QSR RESTAURANT BRANDS INTL INC | Q2 2015 | 13 of 176 | 3.4% | Exited by Q4 2019 | +86% |
| PFE PFIZER INC | Q3 2015 | 16 of 208 | 2.4% | Exited by Q1 2024 | −3.4% |
| GOOG ALPHABET INC | Q4 2015 | 21 of 350 | 5.0% | Held at last filing, Q2 2026 | +831% |
| NWL NEWELL BRANDS INC | Q2 2016 | 14 of 156 | 5.2% | Exited by Q4 2016 | +8.4% |
| CHTR CHARTER COMMUNICATIONS INC N | Q2 2016 | 15 of 269 | 12.4% | Exited by Q1 2021 | +189% |
| USFD US FOODS HLDG CORP | Q3 2016 | 7 of 183 | 1.0% | Held at last filing, Q2 2026 | +333% |
| OPLN KAR AUCTION SVCS INC | Q4 2016 | 13 of 132 | 0.9% | Exited by Q1 2018 | +19% |
| CRM SALESFORCE INC | Q4 2016 | 18 of 303 | 1.4% | Exited by Q1 2026 | +287% |
| UNH UNITEDHEALTH GROUP INC | Q4 2016 | 26 of 299 | 1.7% | Held at last filing, Q2 2026 | +160% |
| CPRT COPART INC | Q1 2017 | 12 of 178 | 0.4% | Exited by Q1 2022 | +390% |
| FMC F M C CORP | Q1 2017 | 12 of 157 | 2.3% | Exited by Q4 2018 | +25% |
| MAR MARRIOTT INTL INC NEW | Q2 2017 | 11 of 182 | 3.2% | Exited by Q4 2022 | +40% |
| NSC NORFOLK SOUTHERN CORP | Q4 2017 | 21 of 205 | 2.3% | Exited by Q3 2020 | +21% |
| DE DEERE & CO | Q1 2018 | 15 of 185 | 2.0% | Exited by Q2 2020 | −11% |
| BA BOEING CO | Q1 2018 | 19 of 221 | 5.9% | Exited by Q1 2025 | −46% |
| PBF PBF ENERGY INC | Q2 2018 | 12 of 153 | 1.1% | Exited by Q4 2018 | +19% |
| BSX BOSTON SCIENTIFIC CORP | Q3 2018 | 14 of 193 | 2.1% | Held at last filing, Q2 2026 | +11% |
| IQV IQVIA HLDGS INC | Q4 2018 | 12 of 207 | 9.2% | Held at last filing, Q2 2026 | +66% |
| KBR KBR INC | Q2 2019 | 7 of 151 | 1.9% | Exited by Q1 2022 | +91% |
| KMB KIMBERLY CLARK CORP | Q2 2019 | 8 of 130 | 2.4% | Exited by Q4 2019 | +6.6% |
| IR INGERSOLL-RAND PLC | Q2 2019 | 14 of 131 | 2.4% | Exited by Q1 2020 | +6.0% |
| LMT LOCKHEED MARTIN CORP | Q2 2019 | 16 of 178 | 5.8% | Exited by Q4 2019 | +7.3% |
| LHX L3HARRIS TECHNOLOGIES INC | Q3 2019 | 2 of 160 | 4.4% | Exited by Q3 2020 | −19% |
| NVST ENVISTA HLDGS CORP | Q3 2019 | 5 of 137 | 0.2% | Exited by Q1 2020 | +6.3% |
| FICO FAIR ISAAC CORP | Q3 2019 | 13 of 186 | 0.5% | Exited by Q1 2020 | +23% |
| LYFT LYFT INC | Q3 2019 | 17 of 258 | 1.2% | Exited by Q2 2021 | +55% |
| SPCE VIRGIN GALACTIC HOLDINGS INC | Q4 2019 | 1 of 98 | 1.5% | Exited by Q2 2020 | +28% |
| GFL GFL ENVIRONMENTAL INC | Q1 2020 | 2 of 120 | 1.2% | Exited by Q3 2023 | +158% |
| STRO SUTRO BIOPHARMA INC | Q1 2020 | 7 of 82 | 0.02% | Exited by Q4 2025 | −91% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | Q1 2020 | 9 of 91 | 0.02% | Exited by Q2 2026 | +163% |
| INSM INSMED INC | Q1 2020 | 12 of 180 | 0.03% | Exited by Q1 2026 | +986% |
| RPRX ROYALTY PHARMA PLC | Q2 2020 | 2 of 124 | 2.2% | Exited by Q4 2024 | −42% |
| OTIS OTIS WORLDWIDE CORP | Q2 2020 | 6 of 147 | 3.2% | Exited by Q1 2023 | +38% |
| APH AMPHENOL CORP | Q2 2020 | 9 of 186 | 1.5% | Held at last filing, Q2 2026 | +636% |
| MRNS* MARINUS PHARMACEUTICALS INC | Q3 2020 | 7 of 68 | 0.2% | Exited by Q4 2024 | – |
| GH GUARDANT HEALTH INC | Q3 2020 | 14 of 182 | 0.9% | Exited by Q2 2021 | +37% |
| OPEN OPENDOOR TECHNOLOGIES INC | Q4 2020 | 2 of 145 | 2.5% | Exited by Q1 2022 | −36% |
| 290A CHINOOK THERAPEUTICS INC | Q4 2020 | 6 of 77 | 0.1% | Exited by Q3 2023 | +142% |
| PWR QUANTA SVCS INC | Q4 2020 | 16 of 179 | 0.9% | Exited by Q1 2022 | +59% |
| EYPT EYEPOINT INC | Q1 2021 | 3 of 87 | 0.2% | Held at last filing, Q2 2026 | +41% |
| PSFE PAYSAFE LIMITED | Q1 2021 | 4 of 90 | 2.6% | Exited by Q3 2021 | −10% |
| FULC FULCRUM THERAPEUTICS INC | Q1 2021 | 5 of 95 | 0.3% | Held at last filing, Q2 2026 | −69% |
| 430 TERNS PHARMACEUTICALS INC | Q1 2021 | 6 of 138 | 0.4% | Exited by Q2 2024 | −70% |
| GLUE MONTE ROSA THERAPEUTICS INC | Q2 2021 | 6 of 83 | 0.05% | Held at last filing, Q2 2026 | +6.6% |
| HWM HOWMET AEROSPACE INC | Q2 2021 | 11 of 169 | 0.9% | Exited by Q4 2021 | −9.5% |
| MQ MARQETA INC | Q2 2021 | 12 of 127 | 0.2% | Exited by Q3 2022 | −71% |
| NTRA NATERA INC | Q2 2021 | 15 of 167 | 0.6% | Held at last filing, Q2 2026 | +139% |
| ACLXGBX ARCELLX INC | Q1 2022 | 2 of 105 | 0.7% | Exited by Q4 2024 | +1091% |
| COGT COGENT BIOSCIENCES INC | Q2 2022 | 9 of 121 | 0.2% | Exited by Q2 2024 | −26% |
| PROK PROKIDNEY CORP | Q3 2022 | 2 of 42 | 1.2% | Held at last filing, Q2 2026 | −77% |
| BHVN BIOHAVEN LTD | Q3 2022 | 3 of 126 | 0.02% | Held at last filing, Q2 2026 | +142% |
| CEG CONSTELLATION ENERGY CORP | Q4 2022 | 21 of 237 | 1.6% | Exited by Q3 2023 | +6.2% |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | Q1 2023 | 8 of 102 | 0.4% | Held at last filing, Q2 2026 | +138% |
| ZURA ZURA BIO LTD | Q2 2023 | 2 of 70 | 1.3% | Held at last filing, Q2 2026 | −28% |
| AVBP ARRIVENT BIOPHARMA INC | Q1 2024 | 4 of 52 | 1.2% | Held at last filing, Q2 2026 | +95% |
| CTNM CONTINEUM THERAPEUTICS INC | Q2 2024 | 1 of 51 | 1.5% | Held at last filing, Q2 2026 | −6.9% |
| BIOA BIOAGE LABS INC | Q3 2024 | 3 of 61 | 1.1% | Exited by Q2 2025 | −82% |
| PVLA PALVELLA THERAPEUTICS INC NE | Q4 2024 | 2 of 54 | 0.3% | Held at last filing, Q2 2026 | +1174% |
| AURA AURA BIOSCIENCES INC | Q1 2025 | 5 of 47 | 0.6% | Held at last filing, Q2 2026 | +21% |
| FTH FAETH THERAPEUTICS INC | Q1 2026 | 2 of 28 | 0.03% | Held at last filing, Q2 2026 | −21% |
Concentration and tenure
- 7.7%
- Median largest position, all quarters The largest single position as a share of the reported equity book.
- 47.6%
- Median top 10 weight, all quarters The ten largest positions together, as a share of the reported equity book.
- Concentrated
- Style, by median largest position
- 2
- Median completed holding, quarters